查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049227

腫瘤生物相似藥市場報告：按藥物類型、癌症類型、通路和地區分類（2026-2034 年）

Oncology Biosimilars Market Report by Drug Type, Cancer Type, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2025年全球腫瘤生物相似藥市場規模達70億美元。展望未來，預計到2034年，該市場規模將達到363億美元，2026年至2034年的複合年成長率為19.49%。

癌症是文明病，它是由細胞異常增生形成腫瘤而發展而來。目前，許多有效的癌症治療方法都基於生物製藥，包括標靶治療和免疫療法。這些藥物利用細菌、酵母、動植物細胞等生物體生產，生產流程複雜，研發週期長。因此，這些藥物的成本相對較高，加重了癌症治療的負擔。為了降低治療成本，人們越來越關注開發品牌抗癌生物製藥的生物相似藥。這些生物相似藥在療效和安全性方面與原廠生物製藥非常相似，而且由於成本低廉，因此可以顯著降低癌症治療成本。

近年來，由於人口老化和環境惡化等因素，全球癌症發生率持續上升。這些因素，加上癌症治療費用的飆升，加重了世界各地醫療保健系統的負擔。因此，許多國家政府正在推廣生物相似藥，作為控制醫療成本的一種途徑。例如，美國食品藥物管理局（FDA）正在製作宣傳資料，幫助醫生和病人更了解生物相似藥。此外，價格合理的藥物有望促進更早、更廣泛的治療，並改善患者的藥物途徑。而且，用於癌症治療的生物相似藥可能會加劇行業競爭，從而進一步降低生物製藥的價格。推動該市場成長的其他因素還包括品牌生物製藥專利到期以及生物相似藥生產商活性化研發投入。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球腫瘤生物相似藥市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依藥物類型
  • 市場區隔：依癌症類型分類
  • 市場區隔：依分銷通路分類
  • 市場區隔：按地區
  • 市場預測

第6章 市場區隔：依藥物類型分類

  • 單株抗體
  • 免疫調節劑
  • G-CSF
  • 造血因子
  • 其他

第7章 市場區隔：依癌症類型分類

  • 肺癌
  • 結腸癌
  • 子宮頸癌
  • 乳癌
  • 腎癌
  • 胃癌
  • 腦癌
  • 其他

第8章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 其他

第9章 市場區隔：依地區分類

  • 歐洲
  • 亞太地區
  • 北美洲
  • 中東和非洲
  • 拉丁美洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Biocon Limited
    • Celltrion Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Intas Pharmaceuticals Ltd.
    • STADA Arzneimittel AG
    • Pfizer Inc.
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • BIOCAD Biotechnology Company
    • Mylan NV
    • F. Hoffmann-La Roche AG
Product Code: SR112026A1572

The global oncology biosimilars market size reached USD 7.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 36.3 Billion by 2034, exhibiting a growth rate (CAGR) of 19.49% during 2026-2034.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

KEY MARKET SEGMENTATION :

Breakup by Drug Type:

  • Monoclonal Antibody
  • Immunomodulators
  • G-CSF
  • Hematopoietic Agents
  • Others

Breakup by Cancer Type:

  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Breast Cancer
  • Kidney Cancer
  • Stomach Cancer
  • Brain Cancer
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Region:

  • Europe
  • Asia Pacific
  • North America
  • Middle East and Africa
  • Latin America

COMPETITIVE LANDSCAPE:

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology biosimilars industry?
  • What are the key regional markets in the global oncology biosimilars industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global oncology biosimilars industry?
  • What are the key driving factors and challenges in the global oncology biosimilars industry?
  • What is the structure of the global oncology biosimilars industry and who are the key players?
  • What is the degree of competition in the global oncology biosimilars industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncology Biosimilars Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Cancer Type
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibody
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunomodulators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 G-CSF
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Hematopoietic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Colorectal Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cervical Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Breast Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Kidney Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Stomach Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Brain Cancer
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Others
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 Europe
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 North America
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocon Limited
    • 14.3.2 Celltrion Inc.
    • 14.3.3 Dr. Reddy's Laboratories Ltd.
    • 14.3.4 Intas Pharmaceuticals Ltd.
    • 14.3.5 STADA Arzneimittel AG
    • 14.3.6 Pfizer Inc.
    • 14.3.7 Apotex Inc.
    • 14.3.8 Teva Pharmaceutical Industries Ltd.
    • 14.3.9 Sandoz International GmbH
    • 14.3.10 BIOCAD Biotechnology Company
    • 14.3.11 Mylan N.V.
    • 14.3.12 F. Hoffmann-La Roche AG

List of Figures

  • Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2025
  • Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2025
  • Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
  • Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
  • Figure 10: Global: Oncology Biosimilars Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million USD), 2020 & 2025
  • Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2026-2034
  • Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million USD), 2020 & 2025
  • Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million USD), 2026-2034
  • Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million USD), 2020 & 2025
  • Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million USD), 2026-2034
  • Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million USD), 2020 & 2025
  • Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million USD), 2026-2034
  • Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million USD), 2026-2034
  • Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Oncology Biosimilars Market Structure
  • Table 7: Global: Oncology Biosimilars Market: Key Players